Israel's PolyPid raises $22M for its extended-release antibiotic to prevent surgical site infections

Israel's PolyPid just raised $22 million from new investor Shavit Capital and others in a bid to put its lead surgical drug reservoir candidate into Phase III. The candidate releases the antibiotic doxycycline hyclate over four weeks, and is intended for patients suffering from severe open tibia fractures who are at high risk of infection. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.